---
document_datetime: 2025-06-17 10:01:25
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xromi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: xromi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.145674
conversion_datetime: 2025-12-26 17:35:34.098777
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xromi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1692/ 202406   | Periodic Safety Update EU Single assessment - hydroxycarbamide (for centrally authorised product only) | 30/01/2025                          | 24/03/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1692/202406. |
| IB/0024              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing             | 16/09/2024                          | n/a                                         |                                  |                                                                                                                                           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0023  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/03/2024 | 16/05/2024 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xromi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. In section 4.6 of the SmPC it is clarified that 'The recommended duration of contraception in male and female patients following the end of treatment with hydroxycarbamide, should be 3 and 6 months, respectively'. The SmPC and the PL are brought in line with the latest QRD template and the PL section on Warnings and precautions is brought in line with the content of the SmPC. |
| II/0019 | Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 9 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-center study in children with sickle cell anaemia over 9 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.4 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 22/02/2024 | 19/03/2024 | SmPC and PL | Please refer to Scientific Discussion: Xromi-H-C-4837-II- 19.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| PSUSA/1692/ 202306   | Periodic Safety Update EU Single assessment - hydroxycarbamide (for centrally authorised product                                                                                                                                                                                                                                                                                                                                                                                | 11/01/2024   | n/a        | PRAC Recommendation - maintenance   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| IB/0021              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                  | 15/05/2023   | n/a        |                                     |
| IB/0020/G            | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                            | 03/03/2023   | n/a        |                                     |
| PSUSA/1692/ 202206   | Periodic Safety Update EU Single assessment - hydroxycarbamide (for centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                          | 12/01/2023   | n/a        | PRAC Recommendation - maintenance   |
| IAIN/0018/G          | This was an application for a group of variations. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.a.1 - Change of a measuring or administration | 09/01/2023   | 06/02/2023 | SmPC, Labelling and                 |

<div style=\"page-break-after: always\"></div>

|           | device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                   |            |            |                 |                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------|
| IA/0017   | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                  | 22/11/2022 | n/a        |                 |                                                       |
| IAIN/0016 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                              | 10/10/2022 | n/a        |                 |                                                       |
| IA/0014   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                    | 01/06/2022 | 06/02/2023 | Annex II and PL |                                                       |
| IA/0013/G | This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 02/05/2022 | n/a        |                 |                                                       |
| IB/0012   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                    | 02/05/2022 | n/a        |                 |                                                       |
| IB/0011   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                   | 24/03/2022 | n/a        |                 | To provide an updated study of ready biodegradability |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                        |            |            |                 | according to OECD 301                                                                                                                                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                          | 28/02/2022 | 06/02/2023 | Annex II        | To provide an updated RMP to implement the changes required as a result of the Assessment of the 1st PSUR, EMEA/H/C/PSUSA/00001692/202006 for the Risk Management Plan of Xromi 100 mg/ml oral solution. |
| PSUSA/1692/ 202106 | Periodic Safety Update EU Single assessment - hydroxycarbamide (for centrally authorised product only)                                                                                                                                 | 13/01/2022 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                        |
| IB/0008            | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                         | 22/11/2021 | 14/02/2022 | SmPC            |                                                                                                                                                                                                          |
| PSUSA/1692/ 202006 | Periodic Safety Update EU Single assessment - hydroxycarbamide (for centrally authorised product only)                                                                                                                                 | 28/01/2021 | 15/04/2021 | SmPC            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1692/202006.                                                                |
| IB/0005            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                         | 01/04/2021 | n/a        |                 |                                                                                                                                                                                                          |
| IA/0007            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                          | 03/03/2021 | 14/02/2022 | Annex II and PL |                                                                                                                                                                                                          |
| IAIN/0006          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 02/02/2021 | 14/02/2022 | Annex II and PL |                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0004   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   | 16/12/2020   | n/a   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0003 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority     | 04/11/2020   | n/a   |
| IA/0001   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                    | 31/01/2020   | n/a   |